Recro Pharma (NASDAQ:REPH) had its target price raised by Stephens from $17.00 to $23.00 in a report released on Tuesday, November 12th, The Fly reports.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Recro Pharma from a hold rating to a buy rating and set a $15.00 price target for the company in a report on Wednesday, October 30th. Oppenheimer set a $20.00 price target on shares of Recro Pharma and gave the company a buy rating in a report on Friday, August 9th. BidaskClub upgraded shares of Recro Pharma from a buy rating to a strong-buy rating in a report on Tuesday, October 22nd. Finally, ValuEngine cut shares of Recro Pharma from a buy rating to a hold rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $14.90.
NASDAQ REPH traded up $0.40 during trading on Tuesday, reaching $16.54. 112,815 shares of the stock traded hands, compared to its average volume of 376,394. The firm has a market cap of $366.87 million, a price-to-earnings ratio of -6.64 and a beta of -0.40. The stock’s 50-day moving average price is $14.65 and its 200 day moving average price is $11.50. Recro Pharma has a fifty-two week low of $5.53 and a fifty-two week high of $18.20.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.06). The company had revenue of $25.26 million for the quarter, compared to analysts’ expectations of $19.83 million. As a group, equities analysts anticipate that Recro Pharma will post -0.71 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its position in shares of Recro Pharma by 14.9% in the second quarter. BlackRock Inc. now owns 1,292,173 shares of the specialty pharmaceutical company’s stock worth $13,142,000 after purchasing an additional 167,346 shares in the last quarter. Engine Capital Management LP lifted its position in shares of Recro Pharma by 3.8% in the second quarter. Engine Capital Management LP now owns 1,104,546 shares of the specialty pharmaceutical company’s stock worth $11,233,000 after purchasing an additional 40,000 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Recro Pharma by 9.6% in the second quarter. Vanguard Group Inc. now owns 917,121 shares of the specialty pharmaceutical company’s stock worth $9,327,000 after purchasing an additional 80,582 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Recro Pharma by 3.7% in the second quarter. Renaissance Technologies LLC now owns 769,300 shares of the specialty pharmaceutical company’s stock worth $7,824,000 after purchasing an additional 27,100 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its position in shares of Recro Pharma by 11.2% in the second quarter. Panagora Asset Management Inc. now owns 449,596 shares of the specialty pharmaceutical company’s stock worth $4,572,000 after purchasing an additional 45,451 shares in the last quarter. 58.69% of the stock is currently owned by institutional investors and hedge funds.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Featured Article: What is the return on assets (ROA) ratio?
Receive News & Ratings for Recro Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Recro Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.
